In the future, after complete implementation of IFN-free regimens, analysis of polymorphisms at position 70 of HCV 1b core will remain relevant to identify patients at higher risk of HCC development who require immediate treatment. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.